We determined the pharmacokinetics and pharmacodynamics of cisatracurium, one of the 10 isomers of atracurium, in 14 patients with end-stage liver disease undergoing liver transplantation and in 11 control patients with normal hepatic and renal function undergoing elective surgery. Blood samples were collected for 8 h after i.v. bolus administration of cisatracurium 0.1 mg kg
Summary
We determined the pharmacokinetics and pharmacodynamics of cisatracurium, one of the 10 isomers of atracurium, in 14 patients with end-stage liver disease undergoing liver transplantation and in 11 control patients with normal hepatic and renal function undergoing elective surgery. Blood samples were collected for 8 h after i.v. bolus administration of cisatracurium 0.1 mg kg
91
(2 ED 95 ). Plasma concentrations of cisatracurium and its metabolites were determined using an HPLC method with fluorescence detection. Pharmacokinetic variables were determined using noncompartmental methods. Neuromuscular block was assessed by measuring the electromyographic evoked response of the adductor pollicis muscle to train-of-four stimulation of the ulnar nerve using a Puritan-Bennett Datex (Helsinki, Finland) monitor. Pharmacodynamic modelling was completed using semi-parametric effect-compartment analysis. Volume of distribution at steady state was 195 (SD 38) ml kg in control patients (P : 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns). The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P : 0.05), but the clinical effective duration of action (time to 25 % recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns). The recovery index (25-75 % recovery) was also similar in both groups: 15.4 (4.2) min in liver transplant patients and 12.8 (1.9) min in control patients (ns). After cisatracurium, peak laudanosine concentrations were 16 (5) and 21 (5) ng ml 91 in liver transplant and control patients, respectively. In summary, minor differences in the pharmacokinetics and pharmacodynamics of cisatracurium in liver transplant and control patients were not associated with any clinically significant differences in recovery profiles after a single dose of cisatracurium. (Br. J. Anaesth. 1996; 76: 624-628) Cisatracurium besylate (51W89; NIMBEX), one of the 10 isomers of atracurium, is approximately three times more potent than atracurium, with an ED95 of 0.05 mg kg 91 [1] , a similar neuromuscular blocking profile to that of atracurium except for a slower onset [1] [2] [3] [4] and less propensity to release histamine than atracurium [5] . Cisatracurium undergoes spontaneous degradation in the body at physiological pH and temperature by organ-independent Hofmann elimination to form laudanosine and a monoquaternary acrylate metabolite. The monoquaternary acrylate metabolite undergoes hydrolysis by non-specific plasma esterases to form a monoquaternary alcohol [6] . Hydrolysis of cisatracurium by plasma esterases is not an important pathway for elimination of cisatracurium [6] . In contrast, atracurium is eliminated by Hofmann degradation and hydrolysis by non-specific esterases [7, 8] .
Although cisatracurium predominantly undergoes spontaneous degradation by Hofmann elimination [6, 9] , liver disease may be associated with changes in the pharmacokinetics, pharmacodynamics, or both, of cisatracurium. In this study, we evaluated the safety, pharmacokinetics and pharmacodynamics of cisatracurium in adults with end-stage liver disease undergoing liver transplan-tation and in adults with normal kidney and liver function undergoing elective surgery (control patients).
Patients and methods
We studied 25 (18 . Anaesthesia was maintained with isoflurane (0.5 % end-tidal concentration) and 50-70 % nitrous oxide in oxygen. Incremental doses of fentanyl were given if needed. Ventilation was controlled to maintain end-tidal PCO2 at 4.6-5.3 kPa. Arterial pressure was monitored directly using an indwelling radial arterial cannula. Body temperature was maintained at 35.0-37.5 ЊC.
After induction of anaesthesia, neuromuscular function was monitored by supramaximal stimulation of the ulnar nerve at the wrist with repetitive train-of-four stimuli (0.2-ms square waves at a frequency of 2 Hz for 2 s at 20-s intervals) using surface electrodes. The evoked compound electromyogram of thumb adduction (adductor pollicis) was recorded using a Puritan-Bennett Datex (Helsinki, Finland) monitor. After full recovery of neuromuscular transmission from suxamethonium and re-establishment of a baseline evoked response, a single bolus injection of cisatracurium 0.1 mg kg 91 (2 ED95) was administered via an i.v. cannula over a 5-10-s period. The degree of neuromuscular block was described as percentage of control; the height of the first train-of-four response (T1) was compared with the baseline T1 response (T0). Time from injection of cisatracurium to maximum neuromuscular block and the times for T1: T0 to reach 5 %, 25 %, 75 % and 95 % were noted from the tracings. The time for T1: T0 to reach 25 % was considered to be the clinically effective duration of action. Recovery indices (time for T1: T0 to recover from 25 % to 75 % and from 5 % to 95 %) and the time to T4 : T1 ജ 70 % were calculated from these data.
Arterial blood samples (5 ml) were collected before (time 0) and 2, 4, 6, 8, 10, 12, 15, 20, 25, 30, 45, 60, 90, 120, 240 and 480 min after administration of cisatracurium. Blood samples were added to chilled tubes containing ethylenediamine tetra-acetic acid (EDTA), mixed thoroughly, and centrifuged; 1-ml aliquots of plasma were added to 4.0 ml of sulphuric acid 15 mmol litre 91 within 3 min of blood sample collection, mixed thoroughly and stored frozen at 920 ЊC. Urine was collected into bottles containing sodium citrate buffer 0.5 mol litre 91 from an indwelling urinary catheter for 10 h after administration of cisatracurium to estimate renal excretion of cisatracurium.
Plasma and urine concentrations of cisatracurium, laudanosine and the monoquaternary alcohol metabolite (MQA) were quantified by high-performance liquid chromatography with fluorescence detection. The lower limit of quantitation was 10 ng ml 91 for each compound. The coefficients of variation for cisatracurium were : 14 % at concentrations between 10 and 2000 ng ml
91
. The coefficients of variation for laudanosine and MQA were : 9 % and : 13 %, respectively, at concentrations between 15 and 750 ng ml 91 for both analytes. The presence of the monoquaternary acid metabolite was assessed qualitatively by examination of the chromatograms.
Plasma concentrations of cisatracurium and its metabolites were used to construct plasma concentration-time profiles for each patient. Pharmacokinetic analysis was performed using noncompartmental methods to determine area under the concentration-time curve (AUC), plasma clearance (Cl), volume of distribution at steady state (V ss ), and elimination of half-life ) (T ½ of cisatracurium. The maximum concentration (C P max), AUC, T ½ and the ratio of the metabolite AUC to cisatracurium AUC were calculated for the laudanosine and MQA metabolites.
Urine concentration data were used to calculate the total amount of cisatracurium excreted unchanged, amount of metabolites in urine and renal clearance of cisatracurium, laudanosine and MQA.
Plasma cisatracurium concentration and percentage T1 suppression data were analysed using semiparametric effect-compartment analysis [10] to estimate concentrations in the effect-compartment (site of action) and the rate constant (keo) describing the rate of equilibration between plasma concentration and neuromuscular block. The effect-compartment 30 (9) 39 (5)* concentration required to produce 50 % T1 suppression (EC5 0 ), which is an index of patient sensitivity, and the variable (␥) describing the steepness of the effect-compartment concentration vs % T1 suppression curve was calculated using the sigmoid Emax model [11] . In addition, each patient was observed for adverse reactions before (baseline), during and after the treatment phases of the study. In particular, arterial pressure and airway pressures were observed closely to detect evidence of clinically significant histamine release.
One-way analysis of variance was performed to evaluate differences in the calculated variables between the two groups. Statistical significance was assumed at P : 0.05. Values are expressed as mean (SD).
Results
Two patients from the liver transplant group were excluded from the pharmacodynamic analysis because they received clindamycin, which may potentiate the effects of neuromuscular blocking agents. Another three patients were excluded in the liver transplant group for determination of EC50 because of insufficient data to accurately define EC50. There was no difference in EC50 or the degree of maximum neuromuscular block after cisatracurium 0.1 mg kg 91 between the two groups (table 2) . Time to maximum block was shorter in the liver transplant patients, but the clinical effective duration of action (time for T1 : T0 to reach 25 %), times for T1: T0 to reach 5 %, 75 %, and 95 %, recovery indices (time for T1: T0 to recover from 25 % to 75 % and from 5 % to 95 %), and time to T4: T1 ജ 70 % were similar (table 2) . There were no significant differences between the two groups in the rate constant (keo) describing the rate of equilibration between plasma concentration and neuromuscular block or in the variable (␥) describing the steepness of the effect-compartment concentration compared with the % T1 suppression curve (table 2) .
One patient in the liver transplant group did not have complete blood sampling and was eliminated from the pharmacokinetic analysis. Plasma cisatracurium concentration vs time data were similar in the two groups ( fig. 1) . The pharmacokinetic variables of cisatracurium are shown in table 3. Patients with liver disease had a higher clearance and larger volume of distribution at steady state than control patients. However, elimination half-life was similar in both groups. There was no or a poor correlation between albumin concentrations and Cl or V ss . The percentage of cisatracurium recovered unchanged from the urine was 11.4 (6.6)% in 11 liver transplant patients and 14.3 (4.0) % in eight control patients. Renal clearance of cisatracurium was 0.62 (0.32) ml min 91 kg 91 in liver transplant patients (n : 10) and 0.80 (0.26) ml min 91 kg 91 in control patients (n : 8).
Maximum plasma laudanosine concentrations were 16 (5) ng ml 91 and 21 (5) ng ml 91 in liver transplant and control patients, respectively. Maximum plasma MQA concentrations were 73 (14) ng ml 91 and 82 (12) ng ml
91
, respectively. Monoquaternary acid was not detected on any chromatogram from any plasma or urine sample. Table 2 Pharmacodynamic variables for cisatracurium (2 ED95) in liver transplant and control patients (mean (SD)). EC50 : Effect-compartment concentration resulting in 50 % neuromuscular block (n : 9 in liver transplant group); keo : rate constant describing the rate of equilibration between plasma concentration and neuromuscular block; ␥ : variable describing the steepness of the effect-compartment concentration vs % T1 suppression curve. Figure 1 Semi-logarithmic plasma concentration curve of cisatracurium 0.1 mg kg 91 (2 ED95) in liver transplant ( ) (n : 14) and control ( ) (n : 11) patients (mean, SD). T of MQA was 61.9 (9.4) and 39.8 (9.9) min for 11 liver transplant and seven control patients, respectively. The mean amount of laudanosine excreted in the 10-h urine collection period was 602 (280) g in 11 liver transplant patients and 503 (260) g in eight control patients. Renal clearance of laudanosine was 0.6-1.2 ml min 91 kg 91 in two evaluable liver transplant patients. Renal clearance of laudanosine was 1.35 (0.89) ml min 91 kg 91 in four control patients. Mean amount of MQA in urine were 449 (213) and 391 (139) g in 11 liver transplant and eight control patients, respectively. Renal clearance of MQA was 0.59 (0.33) and 0.90 (0.39) ml min 91 kg 91 in liver transplant (n : 8) and control (n : 6) patients, respectively.
There were no clinically significant changes in arterial pressure, heart rate or airway pressure after administration of cisatracurium, and no other untoward effects were noted in any patient after bolus administration of cisatracurium.
Discussion
The pharmacokinetics and pharmacodynamics of cisatracurium were determined in liver transplant and control patients. Cisatracurium is eliminated from the body via Hofmann elimination in the central (plasma) and peripheral (tissue) compartments; elimination from the peripheral compartment cannot be estimated in vivo. Therefore, non-compartmental, rather than compartmental, methods were used to calculate pharmacokinetic variables. Non-compartmental methods are based on the assumption that elimination occurs only from the central compartment. Cl, an exit-site independent variable, is similar whether or not it is determined using compartmental or non-compartmental methods. V ss , however, is underestimated when elimination from the peripheral compartment is ignored (i.e. when non-compartmental methods are used) [12] .
We found that the pharmacokinetic variables (Cl, 1 2 T and V ss ) of cisatracurium in our control patients were similar to those observed in other studies of cisatracurium [3, 13] . In addition, these variables (Cl, 1 2 T and V ss ) in our control patients were similar to those of atracurium in healthy patients [8, [14] [15] [16] [17] . The presence of liver disease changed the pharmacokinetics of cisatracurium to a limited degree: V ss of cisatracurium was approximately 20 % larger and mean plasma clearance was approximately 16 % greater in liver transplant patients than in control patients, although 1 
2
T was not different. Similar findings have been reported for atracurium in patients with liver disease [8, [14] [15] [16] . Because a chemical degradation process (Hofmann elimination) is the major elimination pathway for cisatracurium [9] , the higher clearance in liver transplant patients is most likely explained by the larger volume of distribution rather than a change in organ clearance.
The clinical effective duration of action (time for T1: T0 to reach 25 %) in our control patients was similar to that observed in other studies of cisatracurium [1, 2] . Recovery indices (time for T1 : T0 to recover from 25 % to 75 % and from 5 % to 95 %) in our control patients were similar to those observed by Belmont and colleagues [1] but were shorter than those observed by Boyd and colleagues [2] . The time to maximum block in our control patients was shorter than that found in other studies of cisatracurium [1] [2] [3] [4] . Furthermore, the time to onset for cisatracurium was shorter in liver transplant than in control patients, although the duration of action was similar in both groups. These findings are in contrast with results reported for atracurium: the time to onset of action was longer and the duration of action shorter for atracurium in patients with hepatic dysfunction [18] . It is possible that our patients had more severe liver disease than those studied by Bell and co-workers, as most of their patients had only mild liver disease [18] . Therefore, our patients may have had a more hyperdynamic circulation with higher perfusion of muscles, resulting in a shorter time to onset. A slightly lower EC50 (although not statistically significant) in our patients with liver disease may have contributed to this observation.
Plasma laudanosine and MQA concentrations after cisatracurium 0.1 mg kg 91 were much lower than those observed after administration of atracurium besylate 0.3 mg kg 91 [8] ; this dose of atracurium besylate is less potent than the dose of cisatracurium we used. Although cisatracurium is approximately three times more potent than atracurium expressed in terms of its cation, the dose of atracurium is expressed as its besylate salt, whereas that of cisatracurium is not, indicating that 0.1 mg kg 91 of cisatracurium is equipotent to approximately 0.5 mg kg 91 of atracurium besylate. Peak laudanosine concentrations after atracurium were 180 (80) and 190 (40) ng ml 91 in patients with liver disease and in normal patients, respectively [8] . Similar laudanosine concentrations were observed in another study [16] . However, after cisatracurium, peak laudanosine concentrations were 16 (5) and 21 (5) ng ml 91 in liver transplant and control patients, respectively. Similarly, peak MQA concentrations after atracurium were as high as 480 (180) and 490 (70) ng ml 91 in patients with liver disease and in normal patients, respectively [8] while after cisatracurium, peak MQA concentrations were 73 (14) and 82 (12) ng ml
91
, respectively. These differences may be related, at least in part, to the higher potency of cisatracurium, resulting in less substrate for metabolization.
The number of patients with evaluable 1 2 T data for laudanosine was small and therefore no conclusions can be drawn on the effect of liver disease on the elimination characteristics of laudanosine. Nevertheless, the pharmacokinetics of laudanosine and MQA after cisatracurium in both patients with liver disease and controls were similar to those reported after atracurium [8, 16] . The 1
2
T of laudanosine was also longer in patients with liver disease after atracurium administration [8, 16, 19] , indicating that the liver plays an important role in the clearance of laudanosine. Similar observations have been made for MQA [8] . Because of the altered pharmacokinetics of these metabolites in patients with liver disease, cisatracurium may be the preferred drug compared with atracurium because of the significantly lower plasma concentrations of laudanosine and MQA after equipotent doses of these neuromuscular blocking agents. Liver disease does not appear to have an effect on the urinary excretion of cisatracurium. Similar findings have been published for atracurium [19] . In fact, renal clearance and renal elimination of unchanged drug may be slightly greater for cisatracurium than for atracurium [17, 19, 20] . This may be related to the fact that atracurium contains short-acting isomers that are less likely to appear in the urine.
